Health
Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant – The BMJ
The SARS-CoV-2 vaccine produced by the US biotechnology company Novavax is 95.6% effective against the original variant of SARS-CoV-2 but also provides protection…
The SARS-CoV-2 vaccine produced by the US biotechnology company Novavax is 95.6% effective against the original variant of SARS-CoV-2 but also provides protection against the newer variants B.1.1.7 (85.6%) and B.1.351 (60%), preliminary data from clinical trials show.
Interim results have been released from a phase III trial carried out in the UK with more than 15 000 participants aged between 18 and 84, including 27% over the age of 65. The trial tested two doses of the vaccine administered three…
-
Noosa News16 hours agoMan dies in Brisbane crash, women and girl rushed to hospital
-
Noosa News22 hours agoChilling new details emerge in terrifying childcare centre incident in Peregian Springs on the Sunshine Coast
-
Business21 hours agoAre BHP shares are buy after its results?
-
Noosa News9 hours agoItalian Film Festival, Brisbane: All the Details